Experts are excitedly focused on retatrutide, a innovative drug from Eli Lilly, as a significant breakthrough in physique reduction . Distinct from many earlier approaches, retatrutide is a double -action agonist targeting simultaneously GLP-1 and GIP, substances that affect satiety and glucose